Pacific Biotech, Inc.

Academia Sinica

Wyntek Corporation

Wyntek Diagnostics, Inc.

Other

Genzyme Corporation

Quidel Corporation

Genzyme Diagnostics

Eugene Fan

Ching Huang

Fon-Chiu M Chen

Dou-Mei Wang

Tseng-Rong Tu

Chi-Huey Wong

Siu-Yin Wong

Gregg L Wilson

Herbert Bradfield Cunningham

Michael J Willrodt

Ming-Shian Wu

Michael W Milner

Shu-Ching Cheng

Sung-Hsieh Su

Chia-Feng Li

Alice L Yu

Wen-Bin Yang

Hsien-Yeh Hsu

Leslie Rehg

Chin-Chung Hung

Peishan Lee

Wen-Mai Hsu

Sinfu Tzeng

Theresa Popejoy

Leslie J Rehg

A method for treating hypertriglyceridemia with a composition containing wedelolactone, luteolin, and apigenin. Also provided is a method for reducing the risk of developing hypertriglyceridemia by administering the composition to a subject at risk thereof. The composition can be an extract of

[object Object]

Compositions comprisingmycelia extracts and chromatographically separated polysaccharide-enriched fractions thereof are provided. Methods for extractingmycelia are provided. Compositions for methods for their use in amelioration, prevention and treatment of sepsis, acute endotoxemia and inflammatory responses are disclosed.

A method for treating psoriasis by providing a pharmaceutical composition containing at leastextract and administering a therapeutically effective amount of the composition to a patient in need thereof. Also disclosed is a method for treating psoriasis by first purifyingextract into at least one fraction, then providing a pharmaceutical composition comprising at least one of thefractions, and administering a therapeutically effective amount of the composition to a patient in need thereof. A method for alleviating symptoms of psoriasis is disclosed. The symptoms of psoriasis are alleviated by providing a pharmaceutical composition containing at leastextract and administering an amount of the composition effective to increase at least one of an IL-10 and IL-1Ra expression, whereby the symptoms of psoriasis are ameliorated.

A method for treating an allergy by providing a pharmaceutical composition containing at leastextract and administering a therapeutically effective amount of the composition to a patient in need thereof. Also disclosed is a method for treating an allergy by first purifyingextract into at least one fraction, then providing a pharmaceutical composition comprising at least one of thefractions, and administering a therapeutically effective amount of the composition to a patient in need thereof. A method for alleviating symptoms of an allergy is disclosed. The symptoms of the allergy are alleviated by providing a pharmaceutical composition containing at leastextract and administering an amount of the composition effective to decrease at least one of an IgE and IgG2a level, whereby the symptoms of the allergy are ameliorated.

Compositions and methods for treating allergies, auto-immune diseases, and improving skin condition by ganoderma lucidum (reishi) polysaccharides

A method to determine the presence or absence ofGroup A antigen in a sample, comprising the following steps: extracting the antigen from the sample in an assay chamber with two or less extraction reagents, wherein the two reagents may be added to the assay chamber in no particular sequence; introducing a lateral flow immunochromatographic assay device into the extraction reagents containing the extracted antigen without further addition of reagents or manipulation of the sample; forming an antigen-indicator labeling reagent complex; and determining the presence or absence of the antigen in the sample by the presence or absence of a signal formed by the binding of the antigen-indicator labeling reagent complex to an indicator capture reagent specific for said antigen-indicator labeling reagent complex.

A method to determine the presence or absence of Streptococcus Group A antigen in a sample, comprising the following steps: extracting the antigen from the sample in an assay chamber with two or less extraction reagents, wherein the two reagents may be added to the assay chamber in no particular sequence; introducing a lateral flow immunochromatographic assay device into the extraction reagents containing the extracted antigen without further addition of reagents or manipulation of the sample; forming an antigen-indicator labeling reagent complex; and determining the presence or absence of the antigen in the sample by the presence or absence of a signal formed by the binding of the antigen-indicator labeling reagent complex to an indicator capture reagent specific for said antigen-indicator labeling reagent complex.

Methods of use of one step immunochromatographic device for Streptococcus A antigen

This invention relates to a lateral flow immunochromatographic assay device without a plastic housing. The assay includes a sample receiving region, analyte detection region and end region all made of porous material and capable of lateral flow. The analyte detection region includes labeling reagents, a capture reagent and a control reagent. The back of the porous material is laminated with a semi-rigid material with adequate mechanical strength. The top is partially covered with a thin plastic material so as to leave a portion of the sample receiving region exposed for sample application.

One step immunochromatographic device and method of use

This invention relates to a lateral flow immunochromatographic assay device with an increased range of sensitivity without an increase in the clearance time or the occurrence of false positive results. The indicator reagent for the analyte is located in both a separate labeling reagent region and a discrete zone of the analyte detection region.

Hybrid one-step immunochromatographic device and method of use

A device for assaying biological fluids for molecules contained therein comprising a container, material situated in the container for absorbing fluid and in communication with an antibody or antigen impregnated matrix, wherein the matrix is accessible to the exterior of the container through a funnel shaped aperture in the roof of the container. Further features include a chemical drying agent associated with the container for absorbing moisture, thereby preventing inactivation of the assay reagents, and a filter situated above the antibody or antigen impregnated matrix, and in communication with the matrix through the aperture in the roof of the container. The filter removes interfering substances present in the biological fluids and provides protein blocking agents to the matrix material for decreasing the background of the assay.

Immunodiagnostic device

In response to an express need for an immunoassay device with universal applicability, which further promotes the goals of inventory reduction and simplified, less costly manufacture, a container for holding materials used in conjunction with an immunoassay, having a housing with an inside, an outside, and a top, wherein the top is provided with a plurality of apertures communicating with the inside of the housing, and a thin web of opaque material applied over the top of the housing covering at least one but not all of the apertures.

Solid phase immunoassay device and method of making same

The invention provides a disposable device for collecting, transporting and storing semi-solid or liquid specimens prior to analysis. A sample of the collected specimen is removed from the device for analysis by means of a detachable transferring stick, one area of which is the sample collecting portion of the device and another area of which is an integral handle. The device also provides for the collection of a liquid sample drained from a defined volume of a semi-solid specimen through porous screen and collected on the detachable transferring stick. A sample of the specimen or liquid from it may be flushed from the stick for a qualitative or quantitative determination of analyte. The device is useful in collecting fecal specimens and detecting occult blood therein by a determination of hemoglobin in the specimen itself or in a liquid sample drained therefrom.

Occult blood sampling device and assay

Reaction unit for use in analyzing biological fluids

The invention disclosed herein relates to the field of one-step assays and latex agglutination tests ('LAT'), and provides an improved method of preparing and using a one-step immunoassay, as well as improved methods of preparing coated latex particles for use in diagnostic assays, and especially, immunochromatographic assays.

Immunochromatographic assay and method of using same

Disclosed is a method for detecting analytes in samples of whole blood using solid-phase, permeable support assay devices. The whole blood assays require no steps or reagents other than those necessary to carry out the same analysis on plasma or serum using the devices. The color visualization of the analytical field on which the interpretation of the assay depends is not affected by the presence of intact erythrocytes or any degree of hemolysis in the blood sample.

Growing community of inventors

La Jolla, CA, United States of America

Eugene Fan